Neural Regeneration Research ›› 2023, Vol. 18 ›› Issue (4): 803-804.doi: 10.4103/1673-5374.350700

Previous Articles     Next Articles

Nilotinib: from animal-based studies to clinical investigation in Alzheimer’s disease patients

Annalisa Nobili, Marcello D’Amelio*, Maria Teresa Viscomi*   

  1. Department of Medicine and Surgery, University Campus Bio-Medico; Department of Experimental Neuroscience, IRCCS Santa Lucia Foundation, Rome, Italy (Nobili A, D’Amelio M)
    Department of Life Science and Public Health Section of Histology and Embryology, Università Cattolica del Sacro Cuore; Fondazione Policlinico Universitario “A. Gemelli”, IRCCS, Rome, Italy (Viscomi MT)
  • Online:2023-04-15 Published:2022-10-29
  • Contact: Marcello D’Amelio, PhD, m.damelio@unicampus.it; Maria Teresa Viscomi, PhD, mariateresa.viscomi@unicatt.it.
  • Supported by:
    This work was supported by Linea D.1. 2021 Università Cattolica del S. Cuore (to MTV) and by the Italian Ministry of Health (IT) [Research Grant: RF-2018-12365527, to MDA and MTV]. MDA was supported by the American Alzheimer’s Association [AARG-21-851219], and by Fondazione Roma (Rome, Italy). 

PDF

32

Abstract: Since their first description in the brains of patients suffering from Alzheimer’s disease (AD), more than 100 years ago, extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles have been the principal focus of AD research. However, this focus has led to the failure of several long and promising clinical trials, and the efficacy of new Aβ-targeting drugs to slow down the disease progression is still controversial despite being successful in reducing the Aβ load.